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The Use of Liposomal Bupivacaine in Interscalene Nerve Blocks
Abstract
This paper outlines an educational research project at an urban hospital concerning the standardization
of the use of liposomal bupivacaine (LB) for an interscalene block (ISB). The PICOT question guiding this
project was: In adult surgical patients (P), how does the use of LB for shoulder peripheral nerve blocks, (I)
compared to the administration of plain bupivacaine (PB) for shoulder peripheral nerve blocks, (C) affect
postoperative pain scores (O) within 48 hours after surgery (T)? Using the numerical rating scale (NRS)
for pain, a validated and reliable tool, patients who received LB had their 48-hour pain scores measured
and compared to those patients who received PB. Satisfaction scores at 48 hours, a secondary project
outcome, were assessed using a single question with a response scale of agree very much – disagree
very much. Data was collected over a period of four weeks in those who were appropriate for the project.
Data was collected by telephone and recorded on a data collection tool. Both PB and LB had the same
mean immediate postoperative pain score (mean = 0.57), however, the mean 48-hour postoperative pain
score was lower for those who received LB (mean = 3.29) compared to those who received PB (mean =
6.86). Patients who received LB were more satisfied with their anesthetic care (100% agree very much)
compared to those who received PB (57.14% agree very much). From this data, it was concluded that LB
provides a superior postoperative analgesic and surgical experience in comparison to PB.
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Abstract

This paper outlines an educational research project at an urban hospital concerning the
standardization of the use of liposomal bupivacaine (LB) for an interscalene block (ISB). The
PICOT question guiding this project was: In adult surgical patients (P), how does the use of LB
for shoulder peripheral nerve blocks, (I) compared to the administration of plain bupivacaine (PB)
for shoulder peripheral nerve blocks, (C) affect postoperative pain scores (O) within 48 hours after
surgery (T)? Using the numerical rating scale (NRS) for pain, a validated and reliable tool, patients
who received LB had their 48-hour pain scores measured and compared to those patients who
received PB. Satisfaction scores at 48 hours, a secondary project outcome, were assessed using a
single question with a response scale of agree very much – disagree very much. Data was collected
over a period of four weeks in those who were appropriate for the project. Data was collected by
telephone and recorded on a data collection tool. Both PB and LB had the same mean immediate
postoperative pain score (mean = 0.57), however, the mean 48-hour postoperative pain score was
lower for those who received LB (mean = 3.29) compared to those who received PB (mean = 6.86).
Patients who received LB were more satisfied with their anesthetic care (100% agree very much)
compared to those who received PB (57.14% agree very much). From this data, it was concluded
that LB provides a superior postoperative analgesic and surgical experience in comparison to PB.
Keywords: liposomal bupivacaine, interscalene block, total shoulder arthroscopy
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The Use of Liposomal Bupivacaine in Interscalene Blocks
Pain control after shoulder surgery is vital to facilitating rehabilitation as well as improving
patient satisfaction with their surgical experience. The volume of total shoulder arthroplasty
procedures in the United States has rapidly increased. From 2002 to 2011, the volume of this
surgery performed increased by 66%; in 2011 alone, there were 66,485 patients in the United States
who underwent shoulder arthroplasty procedures (Westermann et al., 2015). Regional anesthesia
utilizing peripheral nerve blockade via an interscalene brachial plexus block serves as a proven
method both to reduce opioid use and to enhance pain control. An ISB may be performed as a
single-shot injection of local anesthetic, with or without LB, or a nerve catheter may be threaded
into the area to provide continuous analgesia. LB, also known as EXPAREL, was first approved
by the Food and Drug Administration (FDA) in 2011 to provide long-lasting pain control for
patients undergoing surgery (Golf et. al., 2011). With the advent of Enhanced Recovery after
Surgery (ERAS) protocols being implemented across hospitals in the United States, LB can serve
as a cornerstone in the pain management of these patients.
Background and Significance
ERAS protocols have become a way to provide patients with a standardized approach to
their care while providing them with treatment that is evidence-based. Multimodal analgesia,
including regional anesthesia, reduces the need for general anesthesia, increases postoperative
recovery and decreases pain (Fleisher, 2018). With the increasing prevalence of shoulder surgeries
performed each year, both patients and hospital systems can benefit from this standardization of
care. At the hospital, both total shoulder arthroscopy and total shoulder arthroplasty patients
receive a multitude of different approaches to their care regarding regional anesthetics. Currently,
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ISBs using either PB or LB are being performed, either by means of a single-shot injection of the
local anesthetic or with the use of a peripheral nerve catheter. LB use in an ISB has been proven
effective in providing long-lasting pain control for those patients who undergo a total shoulder
arthroplasty. Patel et al., (2019) found that brachial plexus blocks with LB improved analgesia and
decreased opioid consumption in patients, compared to patients who received PB for brachial
plexus blocks. LB has been used in a multitude of surgeries with positive effects. Malik and
colleagues (2016) found that LB resulted in lower pain scores, a decrease in opioid consumption,
faster discharge and a reduction in hospital costs in various procedures, including shoulder
surgeries.
Poor pain control can delay patient discharge, and as the hospital moves towards
implementing ERAS protocols, it is important to keep in mind that ERAS itself aims to reduce
hospital length of stay. Implementation of the use of LB in an ISB requires access to the medication
via hospital pharmacy, staff and patient education regarding the effects of LB, and organizational
support to add this medication to a pharmacy formulary.
Problem Statement
An urban hospital, located in Philadelphia, Pennsylvania, is a large teaching hospital with
an established orthopedic department. Despite literature demonstrating the effectiveness of LB for
pain management, patients scheduled for total shoulder arthroscopy at the hospital currently
undergo a multitude of different approaches to peripheral nerve blockade. A cause of this problem
is lack of knowledge regarding the efficacy of LB. The PICOT question guiding this project was:
In adult surgical patients (P), how does the use of LB for shoulder peripheral nerve blocks, (I)
compared to the administration of PB for shoulder peripheral nerve blocks, (C) affect postoperative
pain scores (O) within 48 hours after surgery (T)?
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Literature Review
Search Strategy
A literature review was conducted to establish the best evidence-based sources for
determining the overall effectiveness of LB for an ISB. The database utilized for obtaining articles
was the Cumulative Index of Nursing and Allied Health Literature (CINAHL). This database was
chosen due to the wealth of articles involving patient care and its focus on the realms of nursing,
surgery and anesthesia. Other sources included the New York Society of Regional Anesthesia
website (https://www.nysora.com/) and Handbook of Regional Anesthesia for the Military
(Buckenmaier, 2009). Using the Medical Subject Headings (MeSH) “NOT hip, NOT knee, NOT
ankle”, the search narrowed to those studies pertaining to upper extremities and thoracic surgeries.
When entering the search into CINAHL both “Bupivacaine” AND “peripheral nerve block” were
used to yield 816 studies with a publication date from 2015-2020. Expanders included: apply
related words & also search within the full text of the articles. The search was narrowed by
selecting United States of America (USA) and English, which reached 472 studies. Furthermore,
the search results were narrowed by applying major heading criteria: postoperative pain; pain
management; shoulder, to yield 148 studies. From this, 130 full-text articles were excluded if they
did not specifically assess patient postoperative pain or if they did not address the target anatomical
region.
Search Procedure
One hundred forty eight records were screened in order to determine eligibility for use in

further evaluation. Articles were excluded in this process if the study evaluated different types of
peripheral nerve blocks, such as femoral blocks, and if the study included data from various
surgeries, like hip, knee and ankle procedures. Articles that were not available as full-text were
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also excluded. Key variables that were tracked included postoperative pain scores with the
administration of LB when compared to the use of PB for an ISB, as well as the efficacy and
duration of anesthesia when given LB, whether in a single-shot peripheral nerve block or as a
continuous infusion.
Appraisal Procedures
Once the set of articles and resources relevant to the topic of interest were identified for
the review, the information was appraised by determining study designs and study qualities of
what the results of the studies were, and whether the data was pertinent to the patient population
of interest. The Johns Hopkins Evidence Level and Quality Guide was the tool used to grade and
to evaluate the quality of evidence presented in each article, and the evidence was given a score
from Level I – VI (Dearholt et al., 2018). To further distinguish the quality of evidence, the Johns
Hopkins Tool references a grading scale from high quality (A), good quality (B), and low quality
(C), that was also used to evaluate the research compiled for the review.
Summary of Evidence
The literature review revealed various findings as they pertain to LB and its efficacy in
post-shoulder surgery pain management. The primary finding and goal was to review literature
that addressed the pain levels of shoulder surgery patients who received LB compared to those
patients who received another type of pain modality. As described in the evidence table (see
Appendix A, Table 1), according to Patel et al., (2019) patients who received brachial plexus
blocks with LB had improved analgesia and decreased opioid consumption more significantly
compared to patients who received PB alone for brachial plexus blocks. Similarly, Vandepitte
(2017) showed that even the highest pain score reported in patients given the combination of LB
and PB, was still lower than the highest pain score acknowledged in those patients given PB alone.
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Wang and Zhang (2017) concluded that LB had comparative effectiveness to an interscalene
catheter (ICS) on reducing pain scores and opioid consumption. Namdari (2018) concluded that
less opioids were consumed in patients who received LB post-shoulder arthroscopy versus those
who did not. ICS is one of the methods of analgesia after shoulder arthroscopies, in addition to
single-shot local anesthetics. This pain management modality involves the use of indwelling
catheters and a continuous infusion of a local anesthetic. Current literature suggests that the use of
an LB injection as compared to an indwelling catheter decreases infection risk, decreases the need
to follow up, and decreases the need for infusion equipment (Bromberg, 2017).
Studies that compared the use of an ICS to a single-shot injection of PB showed that lower
pain scores were observed in patients who received a continuous ISB compared to a single-shot
injection block with PB (Malik, 2016). This suggested that a long-acting, continuous method of
local anesthetic delivery was an effective way to manage pain and to decrease opioid consumption
in postoperative patients. A study by Kenes et al., (2015) indicated no difference in pain outcomes
in a continuous ISB versus a single-shot injection of LB. Although this outcome did not confirm
the superiority of one pain modality compared to the other, it clarified one principal factor: that
LB was as effective as an ICS, minus the side effects, previously mentioned, that were commonly
associated with an ICS.
Organizational Assessment
Current organizational assessment shows no clear evidence-based method of pain
management for patients undergoing shoulder arthroscopies. Several factors, such as the current
focus on reduction of the opioid burden in the discharge period and promotion of early ambulation
(which primarily depends on adequate pain management), have demonstrated the importance and
utilization of regional anesthesia. As mentioned above, the hospital has no clear guidelines or
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protocols that speak to evidence-based pain management modalities. As a growing number of
patients in the greater Philadelphia region receive orthopedic surgeries for various injuries, it is
important to explore new, evidence-based methods of pain management, such as the utilization of
LB. The reduction in opioid prescriptions in the post-surgical setting would undoubtedly decrease
morbidity and mortality associated with opioids and encourage early physical therapy and
discharge from inpatient settings. This concern is increasingly important in the post-COVID-19
era, as institutions are working to decrease non-emergent inpatient stays.
Key stakeholders for the implementation of this project included the anesthesia team, both
Certified Registered Nurse Anesthetists (CRNAs) and physician anesthesiologists. Dr. Courtney
Wells, the anesthesiologist lead for regional anesthesia, was a key stakeholder who was pivotal in
implementing the usage of LB. Dr. Jason Pawlosky is a second lead anesthesiologist at the hospital
for performing regional anesthetics and was an active stakeholder during the implementation phase
by assisting with the administration of the ISBs. Furthermore, the orthopedic team at the hospital,
consisting of the surgeons, the residents and the nurse practitioners who managed these patients
postoperatively, were included as key stakeholders. Additionally, the perioperative and
intraoperative nurses, nurse managers, admissions, and other executive leaders at the hospital were
denoted as stakeholders. Pharmacy staff were also included in the list of stakeholders, largely due
to the key role they would play with the addition of LB into a pharmacy formulary. LB is approved
by the FDA for regional blocks for patients undergoing shoulder surgery, however due to the
increased cost of the medication, an organizational buy-in is necessary to add LB to a hospital
formulary. Finally, the patients who underwent shoulder surgery and received peripheral nerve
blocks held the role as stakeholders during the implementation of the project. Each individual
stakeholder provided his or her insights, mobilized resources and actively engaged in the project,
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thereby offering a multidimensional and complete approach necessary to provide the most optimal
patient-centered care and successful implementation of the project.
Project Purpose
The primary purpose of this evidence-based doctoral project was to implement
standardization of the use of LB in an ISB for patients undergoing total shoulder arthroscopy. The
aim was to bring lasting pain relief to a population of specific surgical patients who historically
have had significant postoperative pain. Upper-arm and shoulder surgeries are associated with the
highest opioid consumption among upper-extremity procedures (Kim, et al., 2016), and the
intention was to provide longer-lasting pain control by providing an analgesic modality that lasted
up to 72-hours postoperatively.
Project Scope
This scholarly evidence-based doctoral project was designed to improve pain scores for
those patients undergoing total shoulder arthroscopy. Patients who received an ISB for procedures
other than a shoulder arthroscopy were not included. A convenience sample of 14 patients, seven
patients received PB and seven patients received LB, was included in this educational research
project. The patients who received PB were those scheduled to undergo shoulder surgery at the
hospital, and the patients who received LB were those scheduled to undergo shoulder surgery at
the surgical center. The main resources utilized were the vials of LB, the vials of PB, and the
Pajunk needles needed by the anesthesia providers to perform the nerve blocks. The anesthesia
office was utilized to store the gathered data and to make phone calls for the 48-hour postoperative
survey.
Project Objectives
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The objective of this doctoral project was to decrease postoperative pain scores by
implementing the standardized use of LB in an ISB. For this to be accomplished, the hospital and
the providers who perform these blocks must use LB more frequently within their practice. To
accomplish this end point, the project group educated those physicians who perform these blocks
routinely in regard to the literature that supports the usage of LB to decrease both postoperative
pain and opiate consumption. This education included a short list of pertinent bullet points from
the literature review that supported the usage of LB, as well as visual representations of the project
flow chart (see Figure 1) and data collection forms (see Appendix E and Appendix F). A brief
summary of the implementation plan was included, with the projected start date of the project, and
finally, relative and absolute contraindications for the administration of these blocks. Due to
COVID-19 restrictions, the education was delivered by email to the providers, in the form of a
PowerPoint, with the project group’s contact information in the case that the providers had followup questions regarding the project. With the hope that the results of this project will lead to future
standardized use of LB in an ISB, postoperative pain outcomes will continue to be evaluated, as
well as patient satisfaction with their anesthetic experience.
Project Question
The purpose of this project was to improve postoperative pain scores in patients undergoing
total shoulder arthroscopy by utilizing LB; an evidence-based medication that can help decrease
narcotic utilization and subsequently improve patient pain scores. The clinical question guiding
the goals for this project was, “Does implementing the usage of LB for patients undergoing total
shoulder arthroscopy improve their pain scores in the postoperative period?” Secondarily, patient
satisfaction was also evaluated.
Conceptual and Theoretical Framework
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Conceptual Framework
The conceptual model served to guide the process of implementation of the project, which
is outlined below. After identifying the problem (pain management in post-shoulder arthroscopy
patients) and analyzing the current evidence for the use of LB, the next step was educating
healthcare providers who cared for this patient population and tailor the education to their needs.
Next, the use of LB was monitored and the outcome of the project was evaluated.
Evidence-based practice is inherent to providing safe and cost-effective health care. The
“Iowa Model of Evidence Based Practice to Promote Quality Care” enables healthcare
organizations to use a stepwise approach to resolve a clinical issue with an appropriate intervention
that is based on evidence-based practice (Iowa Model Collaborative, 2017). The Iowa Model is
specifically tailored to help promote excellence in healthcare by using evidence-based practice and
is user friendly to most organizational teams. The first step is identifying the opportunities or issues
within the system that need improvement. The next step involves establishing whether the clinical
problem is localized, organizational or even more universally recognized as an issue. As a team,
postoperative pain management for the patient population undergoing shoulder surgeries was
clinically identified as an issue that was not only organizational (as it related to the hospital), but
also as one that could affect state and national initiatives, and policies specific to pain management.
No specific accrediting agency or regulations needed to approve the use of LB for the project,
since it is an FDA approved medication that is prescribed and is administered to patients for pain,
including at the hospital. The interest in this topic presented at a time when there was a national
push to decrease the societal opioid burden and to decrease the mortality associated with opioids.
The “philosophy of care”, as stated in the Iowa Model, is to alleviate patients’ pain and to expedite
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the speed of recovery, while decreasing adverse events associated with surgeries (via early
ambulation, physical therapy, multimodal pain management, regional anesthesia, etc.).
The process of implementation began with understanding the needs of the patients who
were undergoing shoulder arthroscopies at the hospital and analyzing their preferences as it related
to pain management. Emerging evidence shows that there is a heightened risk of prolonged opioid
misuse among opioid-naïve patients following common shoulder arthroscopies. Changing the
current pain management practice is especially important given the increasing evidence showing
the efficacy of LB in managing postoperative pain (see Appendix A, Table 1).
Undoubtedly, the cost and novelty of this medication was a major constraint to using LB.
A localized treatment protocol or an evidence-based practice guideline would enable the healthcare
providers to implement changes in their practice and to reduce postoperative pain in the studied
population. Next, the team implemented the guidelines and evaluated the process and the
outcomes. A postoperative evaluation of patients’ pain level was done to assess the patient’s pain
level following surgery. As a secondary outcome, an evaluation of the patient’s level of
satisfaction, with his or her anesthetic and effectiveness of analgesia, was assessed in the
postoperative period. The team analyzed and monitored the implementation strategy and decided
since the outcome data showed positive results (as assessed by decreased postoperative pain and
heightened patient satisfaction), the results were disseminated accordingly.
Theoretical Model
As Good discussed in the Middle Range Theory of Acute Pain Management, individuals
who experience the intense discomfort and sensation of pain are likely to have delayed healing and
recovery (Good, 1998). Poor pain management for patients, especially during and after shoulder
surgery, can prolong hospital length of stay, increase medication and narcotic requirements,
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decrease patient satisfaction, and discourage both adequate range of motion and a return to
activities of daily living for the patient. The middle range theory of balance between analgesia and
side effects is most like the Doctor of Nursing Practice (DNP) project at hand. The overarching
phenomenon of the project was to address pain management in surgical patients undergoing
shoulder surgery. Specifically, utilizing evidence-based practice to determine the most adequate
method of providing an ISB for this patient population, and determining if the use of LB for an
ISB was superior to utilizing PB for the block. As seen in Appendix A, Table 1, Evidence of
Studies of Liposomal Bupivacaine Effectiveness, the use of LB has decreased the amount of
postoperative opioid use in certain patient populations, though more research and data are needed
to confirm and to solidify this practice, to create a standardization of care at the hospital.
In agreement with Good’s narrative, there is an increased risk of harmful side effects for
patients when their pain is not managed. For example, when patients need to take opioids, they are
at an increased risk of “side effects such as nausea, itching, and drowsiness” (Good, p.120, 1998).
Good highlights the necessity of this theory in that the balance between effective pain management
and analgesia is imperative for patient safety and “important for ethical, humanitarian, and
economic reasons” (Good, p.123, 1998). The theoretical model equates to the DNP project with
its three main components: multimodal intervention, attentive care, patient participation. After an
integrative review of the current research with the use of LB for an ISB for adult patients
undergoing shoulder surgery, studies have shown positive effects for patients regarding a decrease
in opioid use postoperatively for pain management, and an increase in satisfaction scores. Both
attentive care and patient participation were pursued during the implementation of the DNP
project, with the use of careful patient assessments, from the preoperative period through the
postoperative period, as well as postoperative follow-up surveys. Assessment of the patient’s pain
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status was key to determining the effectiveness of LB, as well as the review of the 48-hour followup surveys to determine satisfaction with the anesthetic received.
This theoretical model provided the conceptual basis for the clinical problem, that was
adequate pain management for adult patients undergoing shoulder surgery, and provided the basis
and rationales for the intervention used during the implementation of the DNP project.
Methods
Setting
In order to successfully collect an adequate amount of data, two facilities were utilized
for the implementation of the project. The first setting for the project was an urban hospital,
specifically the preoperative unit where the orthopedic patients stay before surgery as this was
where the nerve blocks were performed. The nerve blocks are rarely performed after induction of
general anesthesia, so the operating room environment was not included in the project’s
setting. The hospital is an academic-affiliated tertiary medical center which includes a 16-bed
preoperative unit, in addition to a six-bed regional block preoperative area; both of these sections
are staffed by preoperative nurses. Nerve blocks are primarily conducted in the regional block
preoperative section by the attending anesthesiologists after the patient is placed on standard
monitors (to assess pulse oximetry, blood pressure and heart rate) and given supplemental
oxygen. Patients scheduled to undergo shoulder arthroscopy at the hospital were included in the
project as those patients who received PB in an ISB.
The second setting included in the project was a smaller, outpatient surgical center,
located a few miles away from the hospital, that cared for a comparable patient population.
Similar to the hospital, the nerve blocks are typically performed in the regional block
preoperative section by the attending anesthesiologists. Patients that were scheduled to undergo
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shoulder arthroscopy at the surgical center were included in the project as those patients who
received LB in an ISB.
Participants
Participants included in the implementation of the project were those patients, admitted to
either the hospital or the surgical center, scheduled to undergo shoulder surgery. To have been
eligible for the project, participants needed to meet the criteria that they are between ages 20 – 75
years old and have no significant co-morbidities that preclude them from undergoing a regional
anesthetic, i.e., severe aortic or mitral stenosis, infection at the site or profound coagulation issues.
Once participants were identified to fit the inclusion criteria, the first seven consecutive
participants scheduled to undergo shoulder surgery at the hospital received PB in the ISB. The
same selection criteria was utilized at the surgical center to identify the first seven consecutive and
eligible participants, who received LB in the ISB.
At the hospital, there are roughly eight shoulder arthroscopies performed on a weekly basis.
Comparatively, there is the same number of shoulder arthroscopies performed each week at the
surgical center. Since the surgical center has an abundant supply of LB, an ISB is typically
performed with the administration of LB for patients scheduled for shoulder arthroscopy.
Intervention
The intervention, a follow-up survey to determine if LB was superior to PB in an ISB, was
guided by the conceptual and theoretical frameworks previously described. The implementation
team assessed each patient for pain in the immediate postoperative period, followed by a phone
call 48 hours post-surgery to evaluate both the level of pain, using the same numerical rating scale
(NRS) for pain, as well as satisfaction with the anesthetic received. Responses from the patient
were recorded on a patient specific case report form (see Appendix F), which served as the data
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collection tool for the entirety of the implementation of the project. After the completion of the
intervention period, data was analyzed to compare pain score outcomes (mean ratings) between
the two groups, the LB group and the PB group.
Project Implementation Plan
The implementation strategy for this project was multifaceted and involved various
steps that included healthcare providers, clinical leads, and key stakeholders within the
hospital. As part of the implementation plan, the advantages and the anticipated impact of LB was
highlighted in the education PowerPoint that was provided to the healthcare providers. To create
interest and awareness, the PowerPoint provided key findings of studies that showed the efficacy
of LB and was distributed by email to the anesthesia team members partaking in the project, as
well as to the nurses in the Post Anesthesia Care Unit (PACU), one month prior to implementation
of the project.
While in the preoperative period, eligible patients were identified if they met specific
criteria for regional blockade by the anesthesia team (as specified per American Society of
Anesthesiologists guidelines) and met the DNP project specific inclusion criteria (see Figure
1). Patients were consented for regional anesthesia and educated on its risks and benefits. After
being identified, seven eligible patients received an ISB with PB at the hospital. During the same
implementation period, an additional seven eligible patients received an ISB with LB at the
surgical center. Patients were transported to the operating room, where report was given to the OR
nurse and the anesthesia team about the ISB, and the patient’s participation in the project.
Patients selected for the LB and PB nerve block received standard anesthesia as decided
per the surgery and anesthesia teams. Involving leadership has shown to create a long-lasting
impact on adaptation and sustained use of evidence-based practice interventions (Cullen,
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2012). During the active phase of the implementation plan, healthcare providers were
assisted by the DNP project team members during the procedures where either PB or LB was
used.
In the postoperative period, patients were transported to the PACU and report was given to
the PACU nurse about the patient’s regional anesthesia. The anesthesia team performed a
postoperative evaluation of the patient’s pain level based on the NRS for pain. This pain level was
recorded in both the patient’s electronic health record (EHR) and the case report form (see
Appendix F) and abstracted as an outcome for this project.
On completion of 48-hours of postoperative status, a student registered nurse anesthetist
(SRNA) from the project team contacted the patient by phone to assess the patient’s pain and
satisfaction level, and this information was entered on the patient’s case report form. Follow-up
phone calls were already a standard of practice at both the hospital and the surgical center, and
were usually done by the anesthesiologist who performed the peripheral nerve block, or by a
designated nurse liaison in the PACU, to ensure a patients’ understanding of his or her discharge
instructions. The same NRS for pain that was used in the immediate postoperative period was used
during the call to determine the patient’s current pain level. Additionally, the project team asked a
single question regarding his or her satisfaction with the anesthetic received (see Appendix E). The
data collected from both the immediate postoperative period and the follow-up phone calls was
recorded on the patient specific case report form (see Appendix F), which followed the patient
during the entirety of the project. Participation in this project was continuously
encouraged by requesting feedback on positive or negative results and experiences by the
anesthesia providers, by means of informal discussions during bi-weekly meetings either by a
phone call or in person at the hospital. The project implementation team provided the anesthesia
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providers with updates on the patient experiences with the usage of either LB or PB in the form of
email.
Measures
Pain
Postoperative pain was the outcome of the project; pain was measured using the NRS for
pain (see Appendix E). The NRS requires the patient to rate his or her pain on a defined scale of
0–10, where 0 is no pain and 10 is the worst pain imaginable. This scale is familiar to patients and
allows for data to be measured as a continuous variable. The NRS takes less than a minute to
administer and to score, and serves as a valid scale to measure pain. The NRS has been used in
previous LB implementation projects to assess the patient’s pain after an ISB with LB (Maalouf,
2016). The NRS has been found to have excellent reliability for the measurement of
musculoskeletal pain (Alghadir et al., 2018). In patients with chronic pain conditions, the NRS has
been shown to be accurate and to correlate with visual analog scales of pain; correlations ranged
from 0.86 to 0.95 (Hawker et al., 2011). During the implementation of this project, patients were
asked to utilize the NRS for pain in both the immediate postoperative period and during the followup phone call 48-hours postoperatively.
Patient Characteristics
Patient age, gender, body mass index (BMI) and race were extracted from the EHR, in
addition to the anesthetic modality received (LB or PB).
Patient Satisfaction with Anesthesia
Numerous patient satisfaction scoring systems exist in the anesthesia literature, however,
a recent systematic review revealed that although specific satisfaction assessment scales lack
reliability, there is an overall lack of standardized, reliable and valid questionnaires to assess
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satisfaction among patients undergoing anesthesia (Pratamaporn, 2009). A single statement, “I was
satisfied with my anesthetic care”, with responses 1,2,3,4,5 and 6 (where 1= disagree very much,
2 = disagree moderately, 3= disagree slightly, 4= agree slightly, 5= agree moderately, 6= agree
very much) was asked during the follow-up phone calls to assess patient satisfaction with
anesthesia.
Data Management Plan
Data Collection
The outcome data for this project comprised of the postoperative pain and satisfaction
scores reported from the patients who were included in the project. Pain scores were evaluated in
the PACU according to the NRS for pain, and both satisfaction and pain scores were collected 48
hours after surgery during a phone call with the patient. This data was collected for both LB and
PB groups; pain scores were evaluated as soon as the patient could score his or her pain level prior
to discharge from the PACU, which was clinically recorded on the patient specific case report form
(see Appendix F). After 48 hours post-surgery, members of the project team contacted patients by
phone to assess the level of pain, using the same NRS utilized in the immediate postoperative
period, and to determine patient satisfaction, and the data was recorded on the same patient specific
case report form (see Appendix F).
The phone calls were made by the project leaders from the hospital’s anesthesia office 48
hours following surgery. After obtaining verbal permission from the patient, patient contact
numbers were taken from the EHR. The data received during these phone calls, as well as the
immediate postoperative pain scores in the PACU, was recorded on a patient specific case report
form (see Appendix F). These case report forms served as the data collection tool for project
implementation. If the team leaders were unable to reach the patient, a voicemail was left with a
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designated return phone number, and the case report form was marked as having received a call
and flagged for the missing data values. The compiled data was securely maintained in the
anesthesia office at the hospital, accessible to only the project team members. The team ensured
the feasibility of these steps during the pilot project phase prior to implementing the project.
Data Maintenance and Transfer
As the data was collected, project leaders monitored the process on a weekly basis, while
concurrently reviewing the data from the previous week. Data transfer from the project data
collection tool (patient specific case reports forms) to a project database was implemented at the
hospital’s medical library into two separate Microsoft Excel 2019 files, completed by two separate
project leaders, and compared for discrepancies by a third project leader. Following this step, the
data was entered into the created Research Electronic Data Capture (REDCap) instrument (version
1), which ensured ease of data transfer for final analysis. Any discrepancies were resolved by the
third project leader, who would access the EHR and case report forms (source data) in order to
correct any erroneous entries.
Before the data transfer step was initiated, patient specific case report forms were verified
and assessed for missing data, extreme values, and ineligible entries; any corrections made to the
patient specific case report forms were done by one SRNA and were submitted to the project leader
for review at the hospital. Missing data on case report forms was obtained by a designated SRNA
using the patient’s EHR at the hospital. The REDCap data collection instrument had an embedded
feature that required a data point to be entered for each question, which served as an additional
checkpoint and verification step to avoid missing values. The finalized and completed database
was password protected.
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Data analysis was performed by all project members, using Microsoft Excel 2019. Prior to
importing data from both the Microsoft Excel 2019 database and REDCap instrument into the final
Microsoft Excel 2019 spreadsheet, a codebook was created utilizing REDCap version 1 software
in order to provide a more comprehensive understanding of the data set. After a final review of the
data, to evaluate for omissions or extreme values, in Microsoft Excel 2019, statistical analysis was
conducted.
Analysis
To better understand and to describe the effect of LB versus the effect of PB in this patient
population, the group determined the relationships between the type of local anesthetic (LB and
PB) and the outcomes of pain and satisfaction scores, as well as whether any statistically significant
differences existed between the LB group and the PB group.
Descriptive Analysis
Due to the small sample size (N=14), the group evaluated the dependent variables via
descriptive statistics by measures of central tendency with mean and median for pain and
satisfaction scores; median scores were prioritized in the descriptive analysis to determine the
value positioned in the middle of the dataset (Landgren, 2008). This method was utilized
primarily due to the small sample size, absence of a normal distribution, and outliers in the data
that were present. Patient characteristic variables included age (20 to 75 years), sex (Male,
Female, Undisclosed), race (American Indian or Alaska Native, Asian, Black or African
American, Native Hawaiian or Other Pacific Islander, White, and Some Other Race) and BMI
(Below 18.5, 18.5 to 24.9, 25 to 29.9, 30.0 and Above). Statistical and visual variability of the
data by bar charts were used. Bar charts were utilized to visually evaluate the differences in pain
and satisfaction scores between the PB group and the LB group.
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Ethical Considerations
The Institutional Review Board (IRB) of the University of Pennsylvania determined that
the project qualified as educational research, or exempt category 1 (see Appendix G). Patient
consent was always collected prior to receiving an anesthetic. Consent for the participation in the
implementation of the project was not required, as the implementation only involved a
postoperative survey to determine the patient’s pain level and satisfaction with the anesthetic.
The patients included in the project were not exposed to any experimental treatment nor withheld
treatment, and the educational research project did not impact the patient’s clinical care. During
the follow-up phone call, an IRB-approved script was utilized by the project leaders to conduct
the survey, and consisted of a statement that the study involved educational research, description
about the study procedures, statement that the research was voluntary, and information about
whom to contact with any questions.
The ethical risks addressed included those of threats to patients’ privacy, due to the
nature of the survey and the data obtained in the patient specific case report forms. In order to
mitigate the risk of patient confidentiality, patient specific case report forms were securely
maintained in a lockbox located in the anesthesia office at the hospital, accessible only to project
team members. The 48-hour follow-up phone calls were conducted solely in the anesthesia office
at the hospital, in order to protect patient privacy and to avoid discussing patient information in
other environments. After completion of data transfer and data management in a secured,
password-protected database, accessible only to project team members, patient specific case
report forms were disposed of in hospital designated and Health Insurance Portability and
Accountability Act (HIPPA) approved shredders at the hospital.
Results
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After accounting for the initial exclusion criteria, 14 patients received an ISB as part of
the anesthesiologists’ clinical management plan prior to undergoing shoulder surgery. Seven
patients, who were scheduled to undergo surgery at the surgical center, received LB as their
anesthetic modality, and seven patients, who were scheduled to undergo surgery at the hospital,
received PB as their anesthetic modality. Two separate bar charts were created in Microsoft
Excel 2019 to examine the differences in mean postoperative pain scores by anesthetic group
(see Figure 2 and Figure 3). An additional clustered bar chart was created to examine the
differences in satisfaction survey responses by anesthetic group (see Figure 4).
As seen in Figure 2, the bar chart displayed the mean immediate postoperative pain
scores by anesthetic group, either LB or PB, for a total sample size of N=14. The mean
immediate postoperative pain score for the PB group (mean = 0.57) was the same as the mean
immediate postoperative pain score for the LB group (mean = 0.57). The PB and the LB group
had equal median immediate postoperative pain scores (median = 0). Results illustrated in Figure
3 demonstrate that the mean 48-hour postoperative pain score for the LB group (mean = 3.29)
was lower than the mean 48-hour postoperative pain score for the PB group (mean = 6.86).
Furthermore, the median 48-hour postoperative pain score for the LB group (median = 2) was
lower than the median 48-hour postoperative pain score for the PB group (median = 7).
Implementation Process Summary
Just prior to project implementation, various changes occurred from the original project
implementation plan to ensure enough data would be gathered for adequate analysis upon
completion of the project. The sample size for LB was decreased due to lack of availability of the
medication, cost of the medication, and physician hesitancy to use the medication. As such, the
number of participants to receive PB was also decreased to allow for equal comparison.
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Due to both the limited availability of LB and the abbreviated schedules of the orthopedic
surgeons, data collection for those participants who received LB took place at an outpatient,
hospital-affiliated surgical center, while data collection for those who received PB remained at the
urban hospital. The surgical center, located in Philadelphia, PA, is a multi-specialty care center
that performs multiple ambulatory surgeries each day, and cares for a similar patient population
that is seen at the hospital. The same anesthesia providers that work at the hospital also frequently
provide care at the surgical center, and the orthopedic surgeons involved in this project rotate to
both the hospital and the surgical center. Prior to implementation of the project, a thorough site
assessment of both locations demonstrated that patient demographics and characteristics were
similar at both facilities, thus allowing for alike comparisons of postoperative pain scores and
satisfaction with anesthesia for those participants who were included in the project. The decision
to collect data at the surgical center, that is only data concerning those patients who received LB,
was made after reviewing the limited schedule of the orthopedic surgeons at the hospital and
discussing with the pharmacy staff at the hospital about the availability of LB. In order for the
group leaders to ensure that data collection for the project could be completed in a timely fashion,
and that there were no large gaps in time between reviewing those patients who received PB and
LB, both the DNP group leaders and key project stakeholders reached the decision to include two
settings for the project.
The IRB of the University of Pennsylvania was contacted, prior to project
implementation, regarding the addition of the second site for data collection. Since the project
qualified as education research, or exempt category 1, no further modifications or adjustments
needed to be made for the project to uphold to IRB approval status (see Appendix G). During the
pre-implementation phase, the site survey of the surgical center confirmed that the anesthesia
providers who work at the center were also present and employed at the hospital. With the large
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quantities of LB available and already in use at the surgical center, staff education regarding the
medication was not necessary, and only education regarding the project was delivered at the
surgical center prior to project implementation.
Project Specific PICOT Question Results
At the start of the DNP project, the aim was to answer the PICOT question, “In adult
surgical patients (P), how does the use of LB for shoulder peripheral nerve blocks, (I) compared
to the administration of PB for shoulder peripheral nerve blocks, (C) affect postoperative pain
scores (O) within 48 hours after surgery (T)?” After analysis of the data, the determination was
made that LB provided superior and lasting analgesia in the postoperative period when compared
to PB. As evidenced above, the mean 48-hour postoperative pain score in the LB group was
lower than the mean 48-hour postoperative pain score in the PB group.
Secondary Results
As a secondary outcome, satisfaction scores in the 48-hour postoperative period were
compared between the LB group and the PB group (see Figure 4). In response to the statement,
“I was satisfied with my anesthetic care”, 100% of the patients in the LB group answered that
they Agree Very Much. In response to that same statement, 57.14% of patients in the PB group
answered that they Agree Very Much, and the remaining 42.86% of patients in the PB group
answered that they Agree Slightly. There were no patients included in the project who responded
to the satisfaction survey statement that they Disagree Very Much, Disagree Moderately, and
Disagree Slightly.
Discussion
Summary

USE OF LIPOSOMAL BUPIVACAINE

26

After completion of data collection and data analysis, the group found that LB was
superior to PB when comparing postoperative pain outcomes. Though both groups had the same
mean immediate postoperative pain scores, the mean 48-hour postoperative pain score was lower
among those who had received LB compared to those who received PB. Additionally, patients
who received LB were more likely to be satisfied with their surgical experience. The PICOT
question the group had set out to answer was to determine which anesthetic modality provided
greater analgesia after shoulder arthroscopy.
Strengths of the project included the lack of missing data from the analysis, as each
patient included in the project was successfully contacted in both the immediate postoperative
period and on a phone call 48-hours postoperatively. This allowed the production of data that
truly represented each patient’s experience with either LB or PB. Another strength included the
statistical analysis, as computing and comparing the measures of central tendency, mean and
median allowed the project leaders to clearly delineate between the two groups in terms of
satisfaction and pain scores.
A major limitation of this project was the small sample size (N=14). The data collection
period under the time constraints of the DNP project schedule allowed the group to collect data
solely within a four-week period. Thus, the results within this project were not generalizable to a
larger population undergoing shoulder arthroscopy. In addition, sampling of these patients was
based on the ease of access the group had to them and how they fit into the group’s selection
criteria. A convenience sample is highly vulnerable to selection bias and influences beyond the
group’s control. For these reasons, future studies should involve multiple hospital centers to
increase the diversity among patients.
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Recommendations for future projects analyzing the differences between LB and PB for
an ISB include collecting a larger amount of data, by expanding either the sample size or the
length of data collection time. If either of these conditions are fulfilled for future projects, the
larger quantity of data may yield a more comprehensive analysis and considerable statistical
differences between the two anesthetic modalities, thereby offering significant implications for
practice.
Implications for Practice
LB was shown to be an effective modality to provide long-lasting analgesia to a patient
population that has long had pain management issues in the postoperative period. The evidence
for the implementation of LB into peripheral nerve blocks is profound and is has been discussed
that “adding LB to standard bupivacaine for interscalene brachial plexus blocks lowered patients’
worst pain scores with major shoulder surgery” (Gil, et al., p.1045, 2019). Those patients who
received LB in an ISB, specifically at the surgical center, were found to have a less painful and
more satisfying perioperative experience. The evidence for the use of LB and the visual
representation of the results from the DNP project suggest that the utilization of LB in an ISB
should be a standard of care at the hospital, as the medication led to effective pain management
and improved quality care that resulted in an enhanced and highly satisfied experience for the
patient.
Sustainability Plan
Since LB is already in use at the hospital, but is not considered a standard of care for
administration in an ISB, positive results from the project serve as rationale to guide the ongoing
quality improvement process of managing postoperative pain for patients undergoing shoulder
surgery at the hospital.
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To ensure that the hospital will standardize the use of LB in an ISB for patients
undergoing shoulder surgeries, it will be critical to have the support and the advocacy from the
entire anesthesia team utilizing the medication and performing the peripheral nerve block.
Ongoing education for the nurses taking care of this patient population, both preoperative and
postoperatively, will be necessary to ensure the team is aware of both the effectiveness and the
benefits of LB. Postoperative phone calls should be performed for patients that receive LB in an
ISB to confirm adequate pain control and patient satisfaction, as well as to report any side effects
that could potentially hinder the use of LB. An appropriate cost analysis will need to be
conducted that supports the use of LB, such that it decreases the consumption of additional
medications as the result from inadequate analgesia and poor pain management. The key
stakeholders at the site will need to coordinate and to develop a plan with the surgeons, hospital
leaders, and pharmacy personnel, that will equip the hospital with a substantial amount of LB to
be utilized for every ISB. With the anticipated hope that LB in an ISB will become a standard of
care at the hospital, ongoing education and training, including updated and relevant evidence
regarding its use, will be required for those providers who will be in direct patient care of those
receiving the medication. Continued monitoring of the use of LB in an ISB for shoulder surgery
will take place, and any pertinent findings or changes will be reported to the hospital
stakeholders to make any necessary clinical practice adjustments.
Conclusions
For those patients scheduled to undergo shoulder arthroscopy, the utilization of LB for
the administration of an ISB attenuated postoperative pain, thus providing an enhanced and
optimal patient experience with the healthcare facility, as well as with the anesthesia received.
Current observed practice at the hospital did not demonstrate a standardization of anesthetics to
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be used for those patients undergoing shoulder arthroscopy, as the medications utilized in the
ISB were chosen based on anesthesia providers’ clinical decision. This educational research
project could help guide implementation of the standardized use of LB in an ISB at any facility
that performs shoulder arthroscopy. The next step that would benefit this educational research
project would be to administer LB in an ISB to a larger patient population. By implementing LB
to a larger population, and continuing to monitor postoperative pain, the benefits, including
superior analgesia and enhanced patient satisfaction, of the medication can lead to the creation of
a definitive protocol for those patients undergoing shoulder arthroscopy.
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Figure 1
Process Flow Chart
Process Flow Chart Start/End
Process Stop Point

Project Implementation
Decision Point

Patient arrives to facility
(hospital or surgical center)
for shoulder surgery

Patient eligible for
regional anesthesia

Process Step

NO

Anesthesia to be
determined by surgical
and anesthesia team

YES

ISB chosen as
anesthetic choice

NO

Anesthesia to be
determined by surgical
and anesthesia team

YES

PROJECT IMPLEMENTATION
Participant included in DNP project and
Case Report Form created for participant

At the hospital, seven eligible participants to
receive PB in ISB

At the surgical center, seven eligible
participants to receive LB in ISB

IN OR

Participant transported
to PACU. Postoperative
pain scores assessed

48-hour postoperative
follow-up call with
participant to assess
postoperative pain scores
and patient satisfaction

Note. Process flow chart was created during the pre-implementation phase of the project.
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Figure 2
Immediate Postoperative Pain Scores

Note. Mean immediate postoperative pain scores are shown for patients’ who received LB and
PB. Pain scores were extracted from the patients’ response to the NRS for pain in the immediate
postoperative period, and the mean pain score was calculated for each anesthetic group.
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Figure 3
48-Hour Postoperative Pain Scores

Note. Mean 48-hour postoperative pain scores are shown for patients’ who received LB and PB.
Pain scores were extracted from the patients’ response to the NRS for pain during the 48-hour
postoperative follow-up phone call, and the mean pain score was calculated for each anesthetic
group.
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Figure 4
Patient Satisfaction Survey Responses

Note. Patient responses to the satisfaction with anesthetic care survey are shown for all patients
included in the project. Responses were collected during the 48-hour postoperative follow-up
phone call, and categorized according to their given response.
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Appendix A
Table 1
Evidence Table of Studies on Liposomal Bupivacaine Effectiveness
Study

Primary
endpoint

Setting

Study
Sample

Design

Intervention (N)

Comparator (N)

Level of
Evidence

Primary outcome :
(+, - or +/-)

Maalouf, et al. (2016)

Postoperative
pain scores

Ambulatory
surgery center

TSA
patients

RCT, prospective
double blind study

ISB with 20 mL
bupivacaine
(n=77)

ISB with 40 mL
bupivacaine
(n=77)

1A

+/-

Patel, et al, (2020)

Postoperative
pain scores

US hospitals
(n=16)

TSA
patients

Double blind RCT

LB injection; 133
mg (n=69)
266mg (n=15)

Normal saline
injection (n=71)

1A

+

Vandepitte, et al. (2017)

Postoperative
pain scores

Ambulatory
surgery center

TSA
patients

Prospective,
double blind study

LB with PB
(n=26)

PB injection
(n=26)

1A

+

Malik et al.(2016)

Postoperative
pain scores

Ambulatory
surgery center

TSA
patients

RCT

Continuous ISB
(n=43)

Single injection
ISB (n=42)

1B

+
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Study

Primary
endpoint

Setting

Study
Sample

Design

Intervention (N)

Comparator (N)

Level of
Evidence

Primary outcome :
(+, - or +/-)

Namdari, et al. (2018).

Postoperative
pain scores

Ambulatory
surgery center

TSA
patients

RCT

Single injection
with LB (n=39)

Single injection
with PB (n=39)

1C

+

Wang, K., & Zhang, H.
(2017)

Postoperative
pain scores

Ambulatory
surgery centers
(n=4)

TSA
patients

Meta-analysis

Single injection
with LB (n= 199)

ISB with PB
(n=311)

1C

+/-

Kenes, et al. (2015)

Postoperative
pain scores

Ambulatory
surgery center

Adult
surgical
patients

Retrospective
cohort study

Single injection
with LB
(n=67)

Continuous
infusion of PB
(n=262)

2A

+/-

Bromberg,et al. (2017)

Postoperative
pain scores
with LB
usage

N/A

Adult
surgical
patients

Literature review

Single injection
with LB

PNC

5C

+

Note. Abbreviations: TSA = Total shoulder arthroplasty. RCT = Randomized control trial. LB = Liposomal bupivacaine. ISB =
Interscalene block. PB = Plain bupivacaine. PNC = Peripheral nerve catheter. PNB = Peripheral nerve block.
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Appendix B

DNP Team and Project Implementation Form
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Appendix C

Project Charter
AIM

The overarching goal of this educational research project is to improve postoperative pain scores among patients
undergoing total shoulder arthroscopy by implementing the standardization of liposomal bupivacaine (LB) in an
interscalene block (ISB) by comparing pain and satisfaction outcomes in shoulder arthroscopy patients who
received LB versus plain bupivacaine (PB).
PROBLEM

The volume of total shoulder arthroplasty procedures in the United States has rapidly increased. From 2002 to 2011
the volume of this surgery performed increased by 66%; in 2011 alone, there were 66,485 patients in the United
States who underwent shoulder arthroplasty procedures (Westermann et al., 2015). Pain management in postshoulder arthroscopy patients is difficult to manage, and often requires an indwelling catheter to deliver anesthesia
while the patients are admitted to the hospital, or a substantial number of opioids to maintain proper analgesia
during both the intraoperative and postoperative period. Inadequate pain management can increase a patient’s
medication requirements, decrease patient satisfaction, and delay patient discharge, all of which can thereby
increase hospital costs.
IMPORTANCE

The evidence for the use of LB suggests that this practice change will provide effective analgesia that is superior to
the use of PB, thereby decreasing additional medications needed for adequate pain management, while
simultaneously increasing patient satisfaction with the quality of care and outcome of the surgical experience. LB
has been shown to achieve clinically meaningful lower cumulative pain scores, reduce opioid requirements,
expedite discharge from the hospital, and reduce hospital costs.
EXPECTED OUTCOMES

It is anticipated to see lower patient reported pain scores in the immediate postoperative period and after 48-hours
postoperatively, and higher satisfaction scores for those patients who receive LB compared to those patients who
receive PB.
MEASURES

The primary outcome of the project is the pain score postoperatively, recorded in the immediate postoperative
period and at 48-hours postoperatively by a team-initiated follow-up survey via phone call. Pain scores will be
measured using the NRS for pain. Patient satisfaction with anesthesia is a secondary outcome measured by a single
Likert scale item during postoperative phone call. Balancing measures to monitor unintended consequences will be
employed. As a balancing measure, the team will monitor adverse events related to or caused by administering
regional anesthesia (as evidenced by patient reports and patient satisfaction scores ).
RISKS/BARRIERS

The major challenges to this project include possible lack of access to LB due to its cost compared to PB, as well as
provider hesitancy to use LB due to its novelty and lack of familiarity. Other challenges include patient retention for
the 48-hour postoperative survey to assess pain and satisfaction scores.
STAKEHOLDERS

The key stakeholders in this educational research project include the anesthesia team performing the block, the
orthopedic surgical team, nursing staff, and pharmacy staff. Multidisciplinary input will be received and assessed
through informal discussions on a bi-weekly basis either via Zoom or in person at the hospital during the regularly
scheduled Thursday morning anesthesia meetings. Patient’s perspective will be evaluated in the postoperative
period by an assessment of satisfaction with the regional anesthetic received.
SCOPE
In Scope:

Out of Scope:

All patients at the hospital and at the All patients at the hospital and at the surgical center scheduled for a surgical
surgical center scheduled to receive procedure who are not receiving an ISB and who are not eligible for regional
an ISB for shoulder surgery
anesthesia, or those who do not consent to being a part of this project.

USE OF LIPOSOMAL BUPIVACAINE
SCHEDULE

Education delivery to pertinent staff - February 2021
Pilot test data collection – March 2021
Study Implementation – May – June 2021
Patient participation and data collection – May- June 2021
Data Analysis – June – July 2021
Results reported to stakeholders – July 2021
PROJECT TEAM

Team Member
Dr. Courtney Wells
Dr. Angela DiDonato
Dr. Jason Palowsky
Ms. Alyssa Aboff
Ms. Kirby Begley
Ms. Dilnoza Nasritdinova

Project Role (sponsor, lead, SME, coordinator, etc.)
Site Lead
Faculty Lead/ Site Lead
Site Lead
Project Leader, SRNA
Project Leader, SRNA
Project Leader, SRNA
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Appendix D

Gantt Chart for N853 (Project Implementation)

2020
2021
December
January
Description

Status

Assignee(s)

Start

End

Days

12-09-20

11-09-20

53 1

2

3

February
4

5

6

7

March
8

Schedule
Untitled

11-09-20

11-09-20

To-dos

Alyssa Aboff, Dil…

30-08-20

30-06-21

N853; JuneTasks

10-06-21

30-06-21

data cleaning and exc…

Alyssa Aboff, Dil…

10-06-21

10-06-21

data analysis using S…

Alyssa Aboff, Dil…

17-06-21

21-06-21

meet with PAH team a…

Alyssa Aboff, Dil…

30-06-21

30-06-21

N853; may Task

07-05-21

28-05-21

Implementation phas…

Alyssa Aboff, Dil…

14-05-21

14-05-21

Implementation phas…

Alyssa Aboff, Dil…

28-05-21

28-05-21

Alyssa Aboff, Dil…

07-05-21

07-05-21

01-04-21

30-04-21

Implementation phas…

23-04-21

23-04-21

Implementation phas…

30-04-21

30-04-21

Implementation phas…

done

N853; April Task

Implementation phas…

done

Alyssa Aboff, Dil…

16-04-21

16-04-21

Implementation phas…

done

Alyssa Aboff, Dil…

09-04-21

09-04-21

Implementation phas…

done

Alyssa Aboff, Dil…

02-04-21

02-04-21

implementation phas…

done

Alyssa Aboff, Dil…

02-04-21

02-04-21

Obtain surgical sched…

done

Alyssa Aboff, Dil…

01-04-21

01-04-21

01-03-21

24-03-21

24-03-21

24-03-21

08-03-21

08-03-21

01-03-21

01-03-21

01-02-21

12-03-21

N853; March Tasks
perform a site survey t…

done

creation of a database

done

Schedule a meeting w…

done

Alyssa Aboff, Dil…
Alyssa Aboff, Dil…

N853; February Tasks

703.0
3.0
3.0

Move into anesthesia …

done

Alyssa Aboff, Dil…

12-03-21

12-03-21

Creation of education …

done

Alyssa Aboff, Dil…

08-02-21

08-02-21

Delivery patient specifi…

done

Alyssa Aboff, Dil…

15-02-21

15-02-21

Create a "mock sched…

done

Alyssa Aboff, Dil…

18-02-21

18-02-21

Set meeting with PAH …

done

Alyssa Aboff, Dil…

01-02-21

01-02-21

Zoom meeting

done

Alyssa Aboff, Dil…

09-02-21

09-02-21

Complete current stat…

done

Alyssa Aboff, Dil…

N852 - Site Problem

30-08-20

12-09-20

20.0

N852 - Available Knowle…

30-08-20

12-09-20

40.0

N852 - Context

13-09-20

26-09-20

50.0

N852 - Problem, Purpos…

27-09-20

10-10-20

30.0

N852 - Conceptual Fram…

27-09-20

10-10-20

10.0

N852 - Intervention

11-10-20

24-10-20

40.0

N852 - Study of the Inter…

11-10-20

24-10-20

20.0

N852 - Measures

25-10-20

07-11-20

50.0

N852 - Analysis

25-10-20

07-11-20

10.0

N852 - Sustainability Plan

25-10-20

07-11-20

10.0

N852 - Implications for p…

25-10-20

07-11-20

N852 - IRB

22-11-20

05-12-20

30.0

N852 - Project Proposal

30-08-20

05-12-20

245.0

10.0

N853 - Pre-Intervention …
Administer handoff su…
Analyze pre-interventio…
N853 - Finalize Project

10-01-21

17-01-21

IRB Approval

10-01-21

17-01-21

5.0

Final approval with sit…

10-01-21

17-01-21

5.0

Final approval with fac…

10-01-21

17-01-21

5.0

N853 - Materials

15.0

10-01-21

17-01-21

Handoff checklist print…

10-01-21

17-01-21

5.0

EPIC checklist smart …

10-01-21

17-01-21

5.0

Checklist education cr…

10-01-21

17-01-21

5.0

N853 - Staff Education

15.0

10-01-21

17-01-21

Educate nurse and pr…

10-01-21

17-01-21

5.0

Educate nurses and p…

10-01-21

17-01-21

5.0

Project ready for imple…

10-01-21

17-01-21

5.0

N853 - Intervention

15.0

10-01-21

17-01-21

Implementation Starts

10-01-21

17-01-21

5.0

Checkin #1 with cham…

10-01-21

17-01-21

5.0

Checkin #2 with cham…

10-01-21

17-01-21

5.0

Checkin #3 with cham…

10-01-21

17-01-21

5.0

Implementation Ends

10-01-21

17-01-21

5.0

N853 - Post Intervention

10-01-21

17-01-21

Administer post interv…

10-01-21

17-01-21

5.0

Data analysis

10-01-21

17-01-21

5.0

Preliminary data revie…

10-01-21

17-01-21

5.0

Intervention completed

10-01-21

17-01-21

5.0

10-01-21

17-01-21

Title

10-01-21

17-01-21

5.0

Abstract

10-01-21

17-01-21

5.0

Introduction

10-01-21

17-01-21

5.0

Methods

10-01-21

17-01-21

5.0

Results

10-01-21

17-01-21

5.0

Discussion

10-01-21

17-01-21

5.0

References

10-01-21

17-01-21

5.0

Tables

10-01-21

17-01-21

5.0

Figures

10-01-21

17-01-21

5.0

23-05-21

23-05-21

23-05-21

23-05-21

N853 - Paper

N854
Add tasks for N854 here

25.0

20.0

45.0

703.0
project:
last update:

Aboff | Nasirtinova | Begley

Calendar event
Todo (pending)

Todo (done)

Due date (pending)

April

May

June

July

9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Aboff | Nasirtinova | Begley

Due date (done)
Single day event
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Appendix E

Numerical Rating Scale for Pain and Satisfaction Question

1. On a scale of 0 – 10, with 0 being no pain and 10 being the worst pain imaginable, how
can you currently rate your level of pain?
2. I was satisfied with my anesthetic care
(1=disagree very much, 2=disagree moderately, 3=disagree slightly, 4=agree slightly,
5=agree moderately, 6=agree very much)
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Appendix F

Case Report Form
•
•
•
•
•
•

Gender:
Age:
Patient Identification Number:
Race:
BMI:
Modality Received:

•
•
•

Post-operative pain in PACU score (NRS scale rating):
Pain at 48 hours via phone call (NRS scale rating):
Satisfaction at 48 hours
o -Question 1:
o -Question 2:
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Appendix G

Institutional Review Board Approval

